Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hutchison China Meditech

15.48
+0.48003.20%
Pre-market: 15.500.0199+0.13%08:12 EDT
Volume:51.05K
Turnover:785.90K
Market Cap:2.70B
PE:5.84
High:15.50
Open:15.12
Low:15.12
Close:15.00
52wk High:21.50
52wk Low:11.51
Shares:174.42M
Float Shares:104.00M
Volume Ratio:0.82
T/O Rate:0.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.65
EPS(LYR):0.2205
ROE:46.90%
ROA:-0.81%
PB:2.20
PE(LYR):70.19

Loading ...

HUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
Mar 20

Cytokinetics announces launch of EARTH-HCM

TIPRANKS
·
Mar 20

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

GlobeNewswire
·
Mar 20

Press Release: Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Dow Jones
·
Mar 20

Oracle Helps Customers Boost Employee Engagement with Strategic Communications and Internal Events

PR Newswire
·
Mar 20

HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ...

GuruFocus.com
·
Mar 20

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Benzinga
·
Mar 20

Stock Track | Hutchison China Meditech Soars 7.36% on Strong 2025 Outlook and Positive Clinical Trial Results

Stock Track
·
Mar 19

Stock Track | Hutchison China Meditech Soars 5.95% Pre-market on Strong 2025 Guidance and Positive Clinical Trial Results

Stock Track
·
Mar 19

Sector Update: Health Care Stocks Steady to Higher Pre-Bell Wednesday

MT Newswires Live
·
Mar 19

Here’s What Lifted Paycom Software (PAYC) Stock up More Than 20%

Insider Monkey
·
Mar 19

Hutchmed's 2024 Earnings, Revenue Fall

MT Newswires Live
·
Mar 19

Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M

TIPRANKS
·
Mar 19

Hutchmed reports FY24 EPS 22c vs. 59c last year

TIPRANKS
·
Mar 19

HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet

Benzinga
·
Mar 19

HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY

Benzinga
·
Mar 19

Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab

TIPRANKS
·
Mar 19

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

GlobeNewswire
·
Mar 19

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 19

Paychex Survey Finds AI is Empowering Small Businesses, with 72% Feeling Positive

Business Wire
·
Mar 18